{
    "cancer_info": {
        "cancer_name": "Systemic Light Chain Amyloidosis"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "History and physical examination",
            "Orthostatic vitals",
            "Serum protein electrophoresis (SPEP)",
            "Serum immunofixation electrophoresis (SIFE)",
            "Serum free light chain (FLC) assay",
            "NT-proBNP",
            "Troponin (T or I)",
            "Lactate dehydrogenase (LDH)",
            "Renal function tests (creatinine, eGFR)",
            "Hepatic function tests",
            "Coagulation studies",
            "Alkaline phosphatase (ALP)",
            "Urine protein electrophoresis (UPEP)",
            "Urine immunofixation electrophoresis (UIFE)",
            "24-hour urine collection for proteinuria",
            "Bone marrow biopsy with Congo red staining",
            "Bone marrow plasma cell FISH (including t(11;14))",
            "Bone marrow cytogenetics/FISH",
            "Tissue biopsy (abdominal fat pad or affected organ) with Congo red staining and amyloid typing",
            "Echocardiogram with global longitudinal strain",
            "Cardiovascular MRI (CMR)",
            "Whole-body low-dose CT",
            "FDG PET/CT",
            "Skeletal survey",
            "Electrocardiogram (ECG)",
            "24-hour urine protein quantification",
            "Endoscopy",
            "Gastric emptying studies",
            "Liver ultrasound or CT for liver span",
            "Electromyography (EMG)",
            "Nerve conduction studies"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Mayo 2012: Stages I-IV based on troponin, NT-proBNP, dFLC; European Modification 2013: Stages I, II, IIIa, IIIb based on troponin T and NT-proBNP",
            "risk_group": "ASCT-eligible (Stage I-IIIa, age <65-75, <3 organs involved, adequate performance status and renal function)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Without significant baseline neuropathy",
                    "plan_name": "Dara-CyBorD induction followed by ASCT",
                    "plan_details": "Daratumumab + cyclophosphamide + bortezomib + dexamethasone for 2-4 cycles, followed by autologous stem cell transplant with high-dose melphalan (140-200 mg/m² based on age, cardiac stage, eGFR)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "With significant baseline neuropathy",
                    "plan_name": "Carfilzomib/dexamethasone induction",
                    "plan_details": "Carfilzomib and dexamethasone for induction, followed by ASCT",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Useful in certain circumstances"
                }
            ]
        },
        {
            "staging_criteria": "Mayo 2012: Stages I-IV based on troponin, NT-proBNP, dFLC; European Modification 2013: Stages I, II, IIIa, IIIb based on troponin T and NT-proBNP",
            "risk_group": "ASCT-ineligible (Stage IIIb, age >75, ≥3 organs involved, poor performance status, renal dysfunction)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Dara-CyBorD",
                    "plan_details": "Daratumumab + cyclophosphamide + bortezomib + dexamethasone",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General",
                    "plan_name": "CyBorD",
                    "plan_details": "Cyclophosphamide + bortezomib + dexamethasone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Bortezomib/dexamethasone (Bd)",
                    "plan_details": "Bortezomib + dexamethasone ± cyclophosphamide",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Melphalan/dexamethasone (MDex)",
                    "plan_details": "Oral melphalan + dexamethasone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Useful in certain circumstances"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Bortezomib/melphalan/dexamethasone (BMDex)",
                    "plan_details": "Bortezomib + melphalan + dexamethasone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General",
                    "plan_name": "VRd",
                    "plan_details": "Bortezomib + lenalidomide + dexamethasone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory Disease (any stage)",
            "risk_group": "Not stage-specific",
            "treatment_plans": [
                {
                    "treatment_line": "Relapsed/Refractory treatment",
                    "patient_subgroup": "Not previously treated with daratumumab",
                    "plan_name": "Daratumumab-based regimens",
                    "plan_details": "Daratumumab single agent or combinations",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Relapsed/Refractory treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Ixazomib-based regimens",
                    "plan_details": "Ixazomib ± dexamethasone or ixazomib + lenalidomide + dexamethasone (IRd)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "Relapsed/Refractory treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Lenalidomide-based regimens",
                    "plan_details": "Lenalidomide + dexamethasone (Rd) or lenalidomide + cyclophosphamide + dexamethasone (RCd)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "Relapsed/Refractory treatment",
                    "patient_subgroup": "t(11;14) positive",
                    "plan_name": "Venetoclax + dexamethasone",
                    "plan_details": "Venetoclax + dexamethasone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "Relapsed/Refractory treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Pomalidomide-based regimens",
                    "plan_details": "Pomalidomide + dexamethasone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "Relapsed/Refractory treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Bendamustine + dexamethasone",
                    "plan_details": "Bendamustine + dexamethasone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "Relapsed/Refractory treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Carfilzomib-based regimens",
                    "plan_details": "Carfilzomib single agent or combinations",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "Relapsed/Refractory treatment",
                    "patient_subgroup": "Prior response to bortezomib or cyclophosphamide",
                    "plan_name": "Re-challenge with prior regimen",
                    "plan_details": "Reuse of previously effective regimens (e.g., bortezomib-based, cyclophosphamide-based)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "dFLC (difference between involved/uninvolved free light chains): Predicts hematologic response; defines complete response (CR: normal FLC ratio + negative immunofixation) and very good partial response (VGPR: dFLC <40 mg/L). NT-proBNP/BNP: Indicates cardiac involvement; used for staging, prognosis, and assessing cardiac response (reduction >30% and >300 ng/L indicates response). Troponins (T/I): Indicate myocardial injury; used for staging and prognosis. 24-hour urine protein: Indicates renal involvement; assesses renal response (reduction >30% or <0.5g/24h without creatinine worsening). t(11;14): Predicts response to venetoclax in relapsed/refractory disease. Serum FLC: Essential for diagnosis, quantifying clonal burden, and response assessment. Cytogenetics/FISH (t(11;14)): Influences therapeutic choice in relapsed/refractory setting."
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：系统性轻链淀粉样变性.txt"
}